Methods for improving cognitive function via modulation of quinone reductase 2
An active agent capable of reducing quinone reductase 2 activity is for use in improvement of cognition in a subject. Such an active agent can be a nucleic acid molecule that reduces the gene expression level of quinone reductase 2 or an inhibitor of quinone reductase 2 activity. A pharmaceutical composition can contain the active agent or a vector containing the active agent.
1. A pharmaceutical composition, comprising a shRNA molecule having a sequence corresponding to SEQ ID NO: 2, 3 or 4, or a vector comprising said shRNA molecule or a nucleic acid molecule encoding said shRNA molecule, and a pharmaceutically acceptable carrier.
2. The pharmaceutical composition of claim 1 , wherein said vector is a modified virus derived from a virus selected from retrovirus, adenovirus, adeno-associated virus, pox virus, alphavirus, herpes virus, or lentivirus.
3. The pharmaceutical composition of claim 2 , wherein said vector is a modified lentivirus.
4. A pharmaceutical composition, comprising (a) a vector comprising a shRNA molecule having a sequence corresponding to SEQ ID NO: 2, 3 or 4 or a nucleic acid molecule encoding said shRNA molecule, and (b) a pharmaceutically acceptable carrier.
5. The pharmaceutical composition of claim 4 , wherein said vector is a modified virus derived from a virus selected from retrovirus, adenovirus, adeno-associated virus, pox virus, alphavirus, herpes virus, or lentivirus.
6. The pharmaceutical composition of claim 5 , wherein said vector is a modified lentivirus.